Market Relevance
The development of new drugs is a highly time- and resources-intensive process in which regularly millions of substances are tested. The discovery of new agents, the shortening of development cycles and the minimization of development risks through the early detection of adverse effects are therefore key criteria in the competition between pharmaceutical and biotech companies.
Getting drugs approved and ready for the market faster brings significant competitive advantages for manufacturers, and gives patients access to effective treatments more quickly.
The discontinuation of drugs due to previously undiscovered serious side effects is always a heavy blow for patients and manufacturers. The healthcare authorities in the EU and the US therefore now stipulate that all newly-approved drugs must be tested for their effects on ion channels in order to prevent adverse effects, especially on the hERG ion channel.
Ion channels are themselves increasingly becoming the target of drug research, since they are involved in many symptoms of disease. Ion channels are already assuming a central role in pain, central nervous system and cardio-vascular research.
If drug research is backed up early on with effective ion channel screening, the choice of substances tested can be accelerated and the drug's risk profile improved. As a result, the chance for a faster and more successful market launch is significantly increased.
flyion makes a significant contribution towards producing accurate measurement data rapidly and cost-effectively and thus plays an important role in optimizing the screening process.
